Cargando…

Comparison of Psychological Difficulties in Patients with Migraine and Epilepsy Using PARADISE-24 Questionnaire

BACKGROUND: Patients with migraine or epilepsy suffer from a wide range of psychological difficulties, and various instruments are needed to separately assess each difficulty. However, the PARADISE-24 questionnaire is a comprehensive questionnaire for evaluating different psychological difficulties...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mirmosayyeb, Omid, Shaygannejad, Vahid, Ghajarzadeh, Mahsa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368128/ https://www.ncbi.nlm.nih.gov/pubmed/32764953 http://dx.doi.org/10.2147/JMDH.S260056

Ejemplares similares

Psychometric Properties of the Persian Version of the Multiple Sclerosis Work Difficulties Questionnaire (MSWDQ) Questionnaire
por: Mirmosayyeb, Omid, et al.
Publicado: (2022)

A Response to: Comparison of Psychological Difficulties in Patients with Migraine and Epilepsy Using PARADISE-24 Questionnaire [Letter]
por: Priastana, I Ketut Andika
Publicado: (2020)

Prevalence of Seizure/Epilepsy in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis
por: Mirmosayyeb, Omid, et al.
Publicado: (2021)

Fear of relapse, social support, and psychological well-being (depression, anxiety, and stress level) of patients with multiple sclerosis (MS) during the COVID-19 pandemic stage
por: Shaygannejad, Vahid, et al.
Publicado: (2021)

Psychometric Properties of the Persian Version of the PARADISE-24 Questionnaire
por: Azimi, Amirreza, et al.
Publicado: (2021)

Screening neuromyelitis optica patients for COVID-19 infection
por: Mirmosayyeb, Omid, et al.
Publicado: (2020)

Predictors of Catching COVID-19 Infection during Pandemic Stage in Patients with Multiple Sclerosis (MS)
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2022)

Psychometric assessment of the Persian version of the patient determined disease steps scale in patients with multiple sclerosis and neuromyelitis optica spectrum disorder
por: Mirmosayyeb, Omid, et al.
Publicado: (2022)

Characteristics of COVID-19 disease in multiple sclerosis patients
por: Barzegar, Mahdi, et al.
Publicado: (2020)

The Prevalence of Migraine in Inflammatory Bowel Disease, a Systematic Review and Meta-Analysis
por: Olfati, Hamide, et al.
Publicado: (2023)

Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2020)

CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series
por: Ebrahimi, Narges, et al.
Publicado: (2023)

Validation of PARADISE 24 and Development of PARADISE-EDEN 36 in Patients with Dementia
por: Talarico, Francesco, et al.
Publicado: (2022)

Comparison of follicular T helper cells, monocytes, and T cells priming between newly diagnosed and rituximab-treated MS patients and healthy controls
por: Yahyazadeh, Sheida, et al.
Publicado: (2022)

Acute CNS demyelination in a subject with cerebellar ataxia following the first dose of COVID-19 vaccine; a case report
por: Mirmosayyeb, Omid, et al.
Publicado: (2021)

Prevalence and risk of developing sexual dysfunction in women with multiple sclerosis (MS): a systematic review and meta-analysis
por: Yazdani, Amid, et al.
Publicado: (2023)

Managing anxiety among multiple sclerosis patients during COVID-19 pandemic
por: Adibi, Iman, et al.
Publicado: (2021)

Is Myasthenia Gravis a Real Complication of the COVID-19 Vaccine? A Case Report-Based Systematic Review
por: Mirmosayyeb, Omid, et al.
Publicado: (2022)

MS Care in Novel Coronavirus 19 Pandemic
por: Ramezani, Neda, et al.
Publicado: (2020)

Fingolimod‐induced bladder lymphoma in a patient with multiple sclerosis
por: Vaheb, Saeed, et al.
Publicado: (2023)

Comparison of Cognitive Rehabilitation versus Donepezil Therapy on Memory Performance, Attention, Quality of Life, and Depression among Multiple Sclerosis Patients
por: Shahpouri, Mohammad Mahdi, et al.
Publicado: (2020)

Paradise
Publicado: (1889)

Editorial: CNS autoimmune disorders and COVID-19
por: Mirmosayyeb, Omid, et al.
Publicado: (2023)

The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): A systematic review and meta-analysis
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2021)

The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis
por: Moghadasi, Abdorreza Naser, et al.
Publicado: (2021)

COVID-19 vaccines and patients with multiple sclerosis: willingness, unwillingness and hesitancy: a systematic review and meta-analysis
por: Yazdani, Amid, et al.
Publicado: (2022)

Bell's palsy after Sputnik V COVID‐19 (Gam‐COVID‐Vac) vaccination
por: Mirmosayyeb, Omid, et al.
Publicado: (2022)

Alternate dosing of fingolimod in relapsing-remitting multiple sclerosis: A systematic review
por: Ghadiri, Fereshteh, et al.
Publicado: (2023)

Trouble in paradise.
por: Lauerman, J F
Publicado: (1997)

Trouble in paradise
por: Brust, Karen B., et al.
Publicado: (2014)

Danger in Paradise
por: Newman, Margaret
Publicado: (2017)

Children’s Paradise
por: Underwood, M. F.
Publicado: (1899)

The Quack’s Paradise
Publicado: (1900)

COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review
por: Barzegar, Mahdi, et al.
Publicado: (2021)

The relationship between retinal layer thickness and cognition in patients with multiple sclerosis: A systematic review of current literature
por: Moghadasi, Abdorreza Naser, et al.
Publicado: (2023)

Neurosarcoidosis in an adult man with a family history of MS: A case report
por: Mirmosayyeb, Omid, et al.
Publicado: (2023)

Olfactory dysfunction in patients with multiple sclerosis; A systematic review and meta-analysis
por: Mirmosayyeb, Omid, et al.
Publicado: (2022)

Association of helicobacter pylori with multiple sclerosis: Protective or risk factor?
por: Mirmosayyeb, Omid, et al.
Publicado: (2020)

Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
por: Nehzat, Nasim, et al.
Publicado: (2021)

Comments on "Trouble in paradise".
por: Tummons, P
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_c0q8pskpch3pe4g7g5cma0qpf9